Migration of human monocytes in response to vascular endothelial growth factor (VEGF) is mediated via the VEGF receptor flt-1

Treatment of human monocytes with vascular endothelial growth factor (VEGF) isolated from tumor cell supernatants was reported to induce monocyte activation and migration. In this study we show that recombinant human VEGF(165) and VEGF(121) had a maximal effect on human monocyte migration at 65 to 250 pmol/L. Chemotactic activity of VEGF(165) was inhibited by a specific antiserum against VEGF, by heat treatment of VEGF(165), and by protein kinase inhibitors. In addition, we could show that VEGF-stimulated monocyte migration is mediated by a pertussis toxin-sensitive GTP-binding protein. Placenta growth factor (PIGF(152)), a heparin-binding growth factor related to VEGF, was also chemotactic for monocytes at concentrations between 2.5 and 25 pmol/L. In accordance with these findings, human monocytes showed specific and saturable binding for I-125-VEGF(165) (half-maximal binding at 1 to 1.5 nmol/L). Using Northern blot analysis, we further could show that human monocytes express only the gene for the VEGF receptor type, fit-1, but not for the second known VEGF receptor, KDR. Resting monocytes expressed low levels of fit-1 gene only. Brief exposure (2 to 4 hours) of human monocytes to lipopolysaccharids, a prototypic monocyte activator, led to a significant upregulation of the fit-1 mRNA level. The results presented here suggest that monocyte chemotaxis in response to VEGF and most likely to PIGF(152) is mediated by fit-1 and thus show a possible function for the VEGF-receptor fit-1. (C) 1996 by The American Society of Hematology.